HISUN(SH:600267) Mei Ri Jing Ji Xin Wen·2025-05-16 12:10Core Insights - The main point of the article is the financial performance and shareholder structure of Zhejiang Hai Zheng Pharmaceutical Co., Ltd. for the year 2024 and the announcement of a share buyback plan [3]. Financial Performance - In 2024, the revenue composition of Hai Zheng Pharmaceutical is as follows: pharmaceutical production accounts for 61.77%, drug sales for 35.86%, other businesses for 2.2%, other industries for 0.09%, and CMO/CDMO/CRO business for 0.08% [1]. Shareholder Structure - As of May 12, 2025, the top ten unrestricted shareholders of Hai Zheng Pharmaceutical are disclosed, with Zhejiang Hai Zheng Group Co., Ltd. holding approximately 321 million shares, representing 26.77% of the total shares [3]. - Other significant shareholders include Zhejiang Provincial International Trade Group Co., Ltd. with about 72.67 million shares (6.07%), and Taizhou Jiaojiang District State-owned Capital Operation Group Co., Ltd. with approximately 59.93 million shares (5%) [3]. - The total shares held by the top ten circulating shareholders amount to approximately 543 million shares, which is 45.34% of the total shares [3].